The CAD Therapeutics Market is Forecast to Show Slow Growth until 2018

Thursday 23 February 2012, Amsterdam

The report is an essential source of information and analysis on the global Atherosclerosis or Coronary Artery Disease (CAD) Therapeutics market. The report identifies the key trends shaping and driving the global Atherosclerosis or Coronary Artery Disease (CAD) Therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global Atherosclerosis or Coronary Artery Disease (CAD) Therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by a team of industry experts.

The CAD Therapeutics Market is Forecast to Show Slow Growth until 2018

The analysis shows that the global Atherosclerosis or Coronary Artery Disease (CAD) therapeutics market stood at $12.0 billion in 2005 and grew at a Compound Annual Growth Rate (CAGR) of 3.8% to reach $14.5 billion in 2010. GlobalData forecasts that the global CAD therapeutics market will grow at a CAGR of 2.1% over the next eight years to reach $17.1 billion by 2018. The current CAD therapeutics market consists of drugs from various therapeutic classes such as statins, Angiotensin- Converting Enzyme (ACE) inhibitors, Beta Blockers (BBs), antiplatelets, Calcium Channel Blockers (CCBs) and nitrates. The current treatment options for CAD mainly include drugs such as Lipitor (atorvastatin calcium), Crestor (rosuvastatin calcium), Angiomax (bivalirudin), Plavix (clopidogrel bisulfate), Norvasc (amlodipine) and Altace (ramipril). The market is expected to show slow growth primarily due to the genericization of key market drugs during the forecast period, which will off-set the effects of the growing prevalence of the disease for the CAD therapeutics market. An increase in the prevalence of CAD is expected in the forecast period, mainly due to increasingly sedentary lifestyles, obesity, hypertension, dyslipidemia, reduction in High Density Lipoprotein Cholesterol (HDL-C) and a high cholesterol diet. The market is set to witness the patent expiration of various drugs, such as Plavix, which went off patent in the EU in 2009 and will lose its US patent in 2012. Lipitor lost its patent in November 2011 in the US and will lose it in 2012 in the EU. Angiomax is set to lose its patent in 2010 in the US and 2015 in the EU. Crestor will lose its patent in 2016 in the US and the EU. These patent expiries will have an impact on the CAD therapeutics market during the forecast period and patients will have access to treatment for CAD at lower prices, reflecting brand erosion of these drugs. However, the expected launch of novel first-in-class (FIC) molecules present in the late stage pipeline and the growing prevalence of the disease will drive the CAD therapeutics market in the coming years.

See figure: Atherosclerosis or CAD Therapeutics, Global, Revenue and Market Forecast ($bn), 2005-2018

Current Competition in the CAD Therapeutics Market is Strong

They found that the current competition in the CAD therapeutics market is strong due to the availability of a wide range of treatment options. The current CAD therapeutics market is well served, with drugs from various therapeutics classes such as statins, CCBs, BBs and nitrates. These drugs are cost effective and most widely prescribed in combination with ACE inhibitors. The presence of other combination products in the market, coupled with the effect of the impending genericization detailed above, will set the scene for a market share war until the launch of new products with high efficacy and safety profiles.

Strong Pipeline Will Drive the Atherosclerosis or CAD Therapeutics Market During the Forecast Period

The research indicates that the CAD pipeline is strong, with 76 molecules in various phases of clinical development. Out of these molecules, 18 are present in Phase III of clinical development process. Most of the molecules in the pipeline are classified as FIC. Out of 76 molecules present in the pipeline, 53 molecules are First-In-Class (FIC), eight are me-too molecules and four are product extensions in various phases of clinical development. Out of 18 molecules present in phase III, the FIC molecules are Anacetrapib, Dalcetrapib, Darapladib, Vorapaxar, Aliskiren, Mipomersen, Generx, Otamixaban and Varespladib. The strong CAD therapeutics pipeline indicates that in the future, the CAD therapeutics market will witness the launch of various molecules with novel disease-modifying modes of action.

Significant Unmet Need Provides Scope for New Entrants

According to the AHA (2010) update, CAD is the cause of about one in every six deaths in the US. In 2010 it was estimated that 78,500 Americans had a new heart attack and around 470,000 had cases of recurrent heart attacks, mostly due to CAD. In the CAD therapeutics market, there is a significant unmet need due to adverse reactions and safety issues related to drugs such as an increased bleeding tendency.This need can be addressed in the future by drugs that have greater efficacy and safety, with a novel mechanism of action and able to prevent secondary cardiovascular events such as Acute Coronary Syndrome (ACS), angina pectoris, stroke or heart attack. The CAD therapeutics market also needs drugs which can increase HDL-C and reduce LDL-C, with minimum side effects and increased efficacy.